rAAV Vector Delivery of TMEM43 for Cardiomyopathy Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cardiomyopathy are inadequate, and there is a need for effective therapeutic options to improve cardiac function and manage symptoms in patients with various types of cardiomyopathy.
Innovation Solution
The use of recombinant adeno-associated virus (rAAV) vectors to deliver transgenes, specifically the TMEM43 coding sequence, into the heart of subjects to treat cardiomyopathy. These vectors include a promoter operably linked to the transgene and are designed to provide physiologically relevant expression levels and restrict expression to cardiac cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for cardiomyopathy are used, then symptom management is provided, but cardiac function improvement is insufficient
Solution Approach 1:
The patent uses recombinant adeno-associated virus (rAAV) vectors as intermediaries to deliver the TMEM43 transgene into cardiac cells. The rAAV vector serves as a mediator between the therapeutic gene and the target tissue, enabling effective gene transfer and sustained expression of functional TMEM43 protein, thereby improving cardiac function in patients with TMEM43-related cardiomyopathy
Solution Approach 2:
The patent employs preliminary action by using a promoter operably linked to the TMEM43 transgene that is designed to provide physiologically relevant expression levels and restrict expression to cardiac cells. This preliminary configuration ensures that once the vector delivers the transgene, the gene is immediately and appropriately expressed in the target tissue without requiring additional regulatory mechanisms
2Reliability
If gene transfer strategies are used to deliver TMEM43 transgene, then cardiac function is improved, but treatment complexity increases
Solution Approach 1:
The rAAV vector design incorporates multiple functions within a single system: it provides efficient gene delivery to cardiac tissue, ensures sustained transgene expression through appropriate promoter selection, and restricts expression to the target tissue. This multi-functional design simplifies the overall treatment approach compared to using separate systems for delivery and regulation
Solution Approach 2:
The patent utilizes parameter changes by optimizing the rAAV vector system with specific promoters and regulatory elements that control the level and timing of TMEM43 expression. By adjusting these parameters (promoter strength, tissue specificity), the system achieves physiologically relevant expression levels that improve cardiac function without requiring overly complex control mechanisms
Data Source
AI summary
The present disclosure relates to compositions and methods for the treatment of cardiomyopathy. Several embodiments provided for herein relate to virally-mediated transfer of a gene to host cells to induce expression of an encoded polypeptide, protein or other product in order to ameliorate one or more symptoms of the cardiomyopathy in a subject. In several embodiments, the disclosed methods and compositions relate to recombinant adeno-associated virus particles encoding human TMEM43 in order to treat Arrhythmogenic cardiomyopathy.